



HAL
open science

Epigenetics, stem cells and epithelial cell fate

Audrey Vincent, Isabelle van Seuningen

► **To cite this version:**

Audrey Vincent, Isabelle van Seuningen. Epigenetics, stem cells and epithelial cell fate. *Differentiation*, 2009, pp.99-107. 10.1016/j.diff.2009.07.002 . hal-02905791

HAL Id: hal-02905791

<https://hal.science/hal-02905791>

Submitted on 29 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



ELSEVIER

Contents lists available at ScienceDirect

Differentiation

journal homepage: www.elsevier.com/locate/diff

Epigenetics, stem cells and epithelial cell fate

Audrey Vincent, Isabelle Van Seuningen *

Inserm U837, Jean-Pierre Aubert Research Center, Team 5 "Mucins, epithelial differentiation and carcinogenesis", Place de Verdun, 59045 Lille Cedex, France

ARTICLE INFO

Article history:

Received 13 February 2009

Accepted 7 July 2009

Keywords:

Differentiation

Stem cells

Epigenetics

Intestinal crypts

Methylation

Histone modifications

Embryogenesis

Cancer

ABSTRACT

Establishment and maintenance of epigenetic profiles are essential steps of development during which stem cells, despite identical genetic information, will acquire different and selective gene expression patterns, specific for their fate. This highly complex programming process involves mechanisms that are not yet completely understood although it has been established over the past few years that chromatin modifier enzymes (i.e. DNA and histone methyltransferases, histone deacetylases, histone demethylases, histone acetyltransferases) play essential roles in the establishment of transcriptional programs accompanying cell differentiation. Investigators in this field have been studying a wide variety of cell types including neural, muscular, mesenchymal and blood cells. This review will focus on epithelial cells of the digestive tract, intestinal stem cell niches being a model of choice to understand how epigenetic changes can drive nuclear programming and specific cell differentiation. Moreover, deregulation of epigenetic programming is frequently observed in human tumours and therefore, decoding these molecular mechanisms is essential to better understand both developmental and cancerous processes.

© 2009 International Society of Differentiation. Published by Elsevier Ltd. All rights reserved.

1. Introduction

The two major features of stem cells are their capacity to self-renew for long period through cell division, and to specialize into multiple differentiated cell types under specific biological conditions. Scientists have been using two types of stem cells in their studies to understand mechanisms involved in differentiation and embryonic development. Embryonic stem cells (ESC) are in vitro derivatives of the inner cell mass of the blastocyst and retain the ability to differentiate into all cell types of an organism along with unlimited self-renewal capacity. Somatic (or adult) stem cells (SSC) come from many adult organs where they ensure tissue homeostasis. Their renewal and differentiation capacities are limited as they only give rise to all the specialized cell types of the tissue from which they originate.

Both embryonic development and stem cell differentiation in adults involve crucial changes in gene expression profiles, pluripotency factors being silenced while specific genes for one differentiated cell type are activated. This reprogramming is not accompanied by changes in the DNA sequence itself and therefore, it has been established that precise and complex epigenetic rearrangements most likely occur during this process (Hattori and Shiota, 2008).

By definition, the term "epigenetic" refers to a heritable change in the pattern of gene expression that is mediated by mechanisms other than alterations in the primary nucleotide sequence of the

gene (Russo et al., 1996). Epigenetic changes in the genome include DNA methylation and histone modifications (acetylation, methylation, phosphorylation, ubiquitination, sumoylation), two mechanisms that are often tightly linked in the regulation of gene expression and involved in many cellular processes (Robertson, 2005). For instance, DNA methylation is a crucial epigenetic modification that drives X-chromosome inactivation, genomic imprinting and chromosome stability while histone modifications govern rearrangement of chromatin structure.

DNA methylation occurs on CpG dinucleotides, is mediated by DNA methyltransferases (DNMTs) and follows a cell-specific profile that is established during development and maintained through cell divisions (Wilson et al., 2006). In the human genome, CpG sites are statistically under-represented but are clustered in GC-rich regions termed CpG islands. These CpG islands are often associated with promoter regions or first exons of half the genes in our genome. In normal and differentiated cells, CpG dinucleotides that are not associated with CpG islands (i.e. 80% of them, predominantly in intergenic and intronic regions of DNA, repeat sequences and transposable elements) are heavily methylated whereas CpG islands are usually unmethylated.

DNA methylation by itself does not directly repress transcription. The process of silencing needs the involvement of the epigenetic machinery that controls histone modifications and therefore chromatin compacting. Chromatin modifier enzymes, including histone deacetylases (HDACs) and histone methyltransferases (HMTs), as well as their competing counterpart histone acetyltransferases (HATs) and histone demethylases (Klose and Zhang, 2007; Santos-Rosa and Caldas, 2005; Agger et al., 2008),

* Corresponding author. Tel.: +33320298867; fax: +33320538562.

E-mail address: isabelle.vanseuningen@inserm.fr (I. Van Seuningen).

are the writers of the histone code, each specific post-transcriptional modification on NH₂-terminal tails of histones being predominantly associated with either gene silencing or activation (Santos-Rosa and Caldas, 2005). In particular, while histone H3 and H4 acetylation is mostly associated with gene expression, di- and trimethylation of H3 lysine 9 (H3K9) and trimethylation of H3K27 elicit the compaction of chromatin and thus gene silencing through the recruitment of heterochromatin protein 1 (HP1) and polycomb group (PcG) proteins, respectively (Bannister et al., 2001; Schlesinger et al., 2007).

Finally, the recent discovery of small non-protein coding RNA named micro-RNAs (miRNAs) that target 3'-untranslated regions (3'-UTR) of genes and either repress messenger RNA maturation or lead to their degradation (Bartel, 2004; He and Hannon, 2004) added a new layer to epigenetic programming of stem cell differentiation.

2. Establishment and reprogramming of epigenetic profiles in early embryonic development

The epigenetic mechanisms involved during the first steps of embryogenesis have been studied for many years and start to be well characterized (Fulka et al., 2008; Heby, 1995).

Within a short period of time after fertilization in mammals, two highly specialized and differentiated parental genomes combine to give rise to an embryo made of totipotent cells with identical genomic characteristics but different fates. Thus, epigenetic rearrangements early after fertilization and during embryogenesis play an evident role in this achievement (Fig. 1). Strongly supporting this statement are initial studies showing the early

lethality of embryos in which genes involved in the establishment of epigenetic marks have been knocked out. Indeed, homozygous mouse embryos mutated for Dnmt1 do not survive past mid-gestation (Li et al., 1992), Dnmt3b-deficient mouse embryos show multiple developmental defects after embryonic day 9.5 and are not viable (Okano et al., 1999) while Hdac1-null mouse embryos die at embryonic day 10 due to severe proliferation defects and retardation in development (Lagger et al., 2002). Since then, many studies have shown that extensive epigenetic remodelling indeed takes place early in the development as well as later during terminal cell differentiation (Fig. 1).

First of all, it has been established years ago that oocytes and spermatozoa harbour different epigenetic profiles, the genome of oocytes being globally less methylated than that of spermatozoa (Monk et al., 1987), which is compacted in protamines in place of histones (Balhorn, 2007).

Moreover, while histone modifications of other differentiated cells have been deciphered and clearly associated with either gene silencing or gene activation, it appears that germ cells harbour a very peculiar histone code. In particular, histone acetylation and di- or trimethylation of H3K4 in fully grown germinal vesicle stage oocytes is not necessarily associated with gene expression (Fulka et al., 2008). When the oocyte re-enters meiosis, histones will be rapidly deacetylated, chromatin being condensed and harbouring essentially repressive histone marks.

Soon after fertilization, replacement of protamines from the paternal pronucleus with acetylated histones from the maternal cytoplasm occurs, along with partial to complete demethylation of the paternal DNA. This process implies active demethylation by yet unknown demethylases. The global decondensation of the chromatin is achieved by slower and progressive acetylation of




Fig. 1. Epigenetic rearrangements play an essential role in early embryonic development. The oocyte genome is globally less methylated than the spermatozoa genome, which is compacted in protamines, rather than deacetylated histones. Soon after fertilization, these two highly specialized genomes will have to dedifferentiate and subsequently redifferentiate to give rise to all the cell types that compose an adult organism. Protamines that wrap the paternal genome are rapidly replaced by acetylated histones, while the maternal genome undergoes a slower and progressive acetylation. Active and passive demethylation of the fertilized egg will perfect the loose chromatin state acquired as of the morula stage (Heby, 1995). At the blastula stage, the cells of the inner cell mass (ICM) become gradually more methylated compared with the cells of the trophectoderm. After implantation, de novo methylation of the genome is ensured by Dnmt3a and Dnmt3b activity. In the later stages of development, terminal differentiation will be accompanied by precise epigenetic rearrangements allowing expression of cell fate-specific genes while genes involved in proliferation or genes specific from other cell fates will be silenced.

maternal pronucleus (Fig. 1).

Passive, replication-dependent DNA demethylation, rather due to inactivation or sequestration in the cytoplasm of DNMTs, subsequently takes over and continues in Mouse and Human until the morula stage, where the lowest methylation level is observed. Importantly, centromeric heterochromatin, allowing correct cell division and chromosome segregation, as well as imprinted genes, which methylation profile is re-established later according to the sex of the embryo, are protected from active and/or passive demethylation.

After implantation, early expression of Dnmt3a and Dnmt3b allows a progressive de novo remethylation of the embryonic genome that will (i) distinguish between cells from the trophectoderm, which give rise to extraembryonic tissues, and cells from the inner cell mass, which give rise to the embryo itself, and (ii) establish a new methylation pattern specific for pluripotent cells that leaves CpG islands mostly unmethylated (Fig. 1).

3. General characteristics of embryonic stem cells upon self-renewal and differentiation

The epigenetic profile of somatic cells is established later during embryonic development when pluripotent cells specialize to give rise to all types of differentiated cells, specific for each organ. ESCs have been an *in vitro* model of choice for understanding how these epigenetic mechanisms are established.

Stem cell status involves multiple layers of molecular events designed to impose flexible but precise control over the expression of genes important for development (Lunyak and Rosenfeld, 2008). Several factors of pluripotency and self-renewal have been identified including the Pou domain containing transcription factor OCT4, NANOG, SOX2, FOXD3, REX1, KLF4, c-myc, Lin-28 and the Wnt signalling pathway (O'Shea, 2004; Yeo et al., 2007). Along with expression of these specific factors, stem cells harbour a peculiar epigenetic landscape with a highly dynamic chromatin state characterized by a distinct DNA methylation profile, the genome of ESCs being globally less methylated than differentiated somatic cells (Bibikova et al., 2006). Structural proteins such as HP1 and histone H1 also bind more loosely to chromatin compared with differentiated somatic cells (Chen and Daley, 2008; Collas et al., 2007). These features are essential for chromatin rearrangements and therefore, global transcriptional programming upon differentiation. More particularly, developmentally regulated genes are characterized by the presence of both active and repressive histone marks, where large regions containing trimethylated K27H3 colocalize with smaller regions containing permissive chromatin marks such as methylated K4H3. This chromatin bivalency allows genes encoding specific transcription factors or early differentiation factors to be prepared for rapid transcriptional activation upon differentiation (Bernstein et al., 2006) and, interestingly, is specifically found where responsive elements for previously mentioned pluripotency factors are located. Indeed, crosstalks between these factors and chromatin modifier enzymes occur at several molecular levels. First, these crosstalks include mutual regulation as the promoters of OCT4 and NANOG genes are unmethylated in undifferentiated human ESCs (Lagarkova et al., 2006) and undergo rapid DNA methylation upon differentiation *in vitro* (Yeo et al., 2007) and after implantation *in vivo* (Lengner et al., 2007), while OCT4 has been shown to bind to intronic sequences of Jmjd1a gene, encoding histone H3K9 demethylase (Loh et al., 2007). Second, Oct4 and Nanog have recently been shown to interact with each other and associate with Hdac1/2 and Metastasis Associated 1/2, in a newly discovered complex named NODE (for Nanog and Oct4-associated deacetylase), which contained HDAC activity comparable to NuRD

complex (Liang et al., 2008). Finally, competition for regulatory elements on key developmental genes between pluripotency factors and chromatin modifier enzymes is indicated by the fact that these factors cannot bind their target genes in differentiated cells due to differences in epigenetic "make-up" of the designated target chromatin (Lunyak and Rosenfeld, 2008).

In stem cells, PcG complex, on the other hand, acts to stabilize a repressive chromatin structure and has been shown to play important roles in the direct silencing of cell differentiation regulators such as Otx2, Satb2 and Tbx3 factors (Pasini et al., 2007) and are part of the preprogrammed memory system established during embryogenesis (Bracken et al., 2006).

Adding to the complexity of epigenetic regulation of stem cell pluripotency, recent studies indicate that miRNAs show distinctive temporal and tissue-specific expression in mammals. miRNAs are endogenous noncoding RNAs, of 18–24 nucleotides in length, typically excised from 60 to 110 nucleotide foldback RNA precursor structures (Calin and Croce, 2006), which play important negative regulatory roles in animals and plants by targeting messenger RNA transcripts for degradation or translational repression, involving the RNA Interference Silencing Complex (RISC) (Bartel, 2004). Recently, Gonzalez and collaborators showed that miRNAs can also trigger transcriptional silencing via chromatin remodelling (i.e. trimethylation of H3K9) at DNA regions containing complementary sequences (Gonzalez et al., 2008). Many miRNAs are specifically expressed during differentiation and embryogenesis, while ESCs, on the other hand, express a unique set of miRNAs (Houbaviy et al., 2003). Moreover, some miRNAs expressed in stem cells are not matured until differentiation process is initiated such as let-7, which processing is inhibited by a feedback loop involving the pluripotency factor Lin-28 (Rybak et al., 2008), strongly suggesting that miRNAs may have a role in the maintenance of the pluripotent cell state and in the regulation of early mammalian development.

Upon differentiation, a unique DNA methylation profile is acquired, reducing cell pluripotency while inducing progressive activation of cell- and tissue-specific genes (Hattori and Shiota, 2008) (Fig. 2). This activity may be due to Dnmt1, since deficiency in this DNA methyltransferase blocks differentiation potential of ESCs (Jackson et al., 2004). Heterochromatic markers, such as HP1 proteins, change their localization from a hyperdynamic state involving plasticity in chromatin organization, to a more concentrated state, stabilizing the new cell fate. Thus, the chromatin becomes progressively less permissive and loose with a decrease in global levels of active histone marks such as acetylated histones H3 and H4 (Chen and Daley, 2008). Cell differentiation is also accompanied by a specific increase in silencing-associated dimethylated K9H3 and trimethylated K9H3 (Wen et al., 2009), but removal of EZH1/EZH2-mediated K27H3 trimethylation (Shen et al., 2008) presumably by newly discovered histone demethylases (Lunyak and Rosenfeld, 2008).

Finally, bivalent chromatin profiles will be changed either to methylated H3K4 at genes specific for the particular cell fate in which the cells are engaged, or to trimethylated H3K27 at genes specific for other cell fates (Bernstein et al., 2006).

4. Somatic stem cell niches in the intestinal crypts: a model for cell differentiation in adults

The adult small intestine is constructed of millions of crypts and villi lined by a single-layered epithelium, each crypt base containing multiple stem cells that give rise to the four types of differentiated cells in the intestinal epithelium: columnar cells specialized for absorption, enteroendocrine cells for secretion of peptides hormones, goblet cells for mucus secretion, and Paneth




Fig. 2. Model for epigenetic regulation in adult intestinal crypts. The anatomy of the intestinal epithelium, shaped into crypts and villi, is depicted on the right-hand side. Stem cells in red give rise to the four other cell types of the epithelium. Three of them, the absorptive or columnar cells, the goblet cells and the enteroendocrine cells, migrate as they differentiate to the top of the villi. The fourth cell lineage, made of Paneth cells, migrates to the bottom of the crypt. Transit amplifying compartment in pink contains the cells having undergone the process of differentiation. Self-renewal of stem cells is ensured by the Wnt signalling pathway, which is regulated by epigenetic mechanisms involving MBD2. Expression profiles along the crypt-villus axis of GATA-5 and CDX-2 transcription factors, involved in terminal differentiation of intestinal epithelium, as well as expression profiles of HDACs and DNMTs, which may play a role in their silencing at the bottom of the crypt, are shown. On the left-hand side, epigenetic modifications involved in regulation of differentiation genes are presented. Lollipops represent CpG sites, open circles being unmethylated cytosines while black circles being methylated cytosines. Histones are shown as pink cylinders. Specific histone modification profiles are established at each step toward differentiated cells. A: Acetylation, M: Methylation. Numbers refer to the lysine residue on histone H3 which tail is post-transcriptionally modified. Reprogramming of epigenetic modifications leads to dedifferentiation and cancer but is potentially reversible, by the use of HDAC or DNMT inhibitors. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

cells which help keep the crypts sterile (Leedham et al., 2005a) (Fig. 2). The self-renewing epithelium of the small intestine is ordered into stem/progenitor crypt compartments and differentiated villi compartments. The maintenance of undifferentiated proliferative cells in crypts and adenomas requires concerted activation of the Notch and Wnt cascades (Fodde and Brabletz, 2007; van de Wetering et al., 2002; van Es et al., 2005). During epithelial renewal, stem cells migrate out of the niche and up the villus while differentiating and die after a week once they have reached the lumen (Crosnier et al., 2006). Thus, intestinal epithelial cell turnover is particularly fast and occurs from a well-identified structure, so-called niche, which provides an optimal microenvironment for stem cells, ensured by epithelial cells, mesenchymal cells and extracellular substrates (Scoville et al., 2008; Walker and Stappenbeck, 2008). Therefore, while ESCs, although a reasonably good model in vitro, harbour epigenetic variations and reprogramming during extended culture (Collas et al., 2007), the intestinal epithelium represents an attractive biological model of differentiation in which most of the previously cited pluripotency and differentiation signalling pathways are involved (Yen and Wright, 2006), even though some differences have been reported. For instance, while Oct4, a well-established regulator of pluripotency in the inner cell mass of the mammalian blastocyst as well as in embryonic stem cells, is detected in a variety of SSC and tumour cells, its activity is dispensable for both self-renewal and maintenance of SSCs in the adult mammal (Lengner et al., 2007).

Over the past years, isolation and growth in culture of intestinal crypts has challenged researchers who have developed elegant methods to be able to decipher mechanisms underlying intestinal SSC differentiation (Cano-Gauci et al., 1993; Tou et al., 2004; Grossmann et al., 1998). Indeed, although the structure of the crypt itself is well characterized and strong evidence of the presence of stem cells in this compartment has been established several decades ago (Marshman et al., 2002), the definitive identification of the proper stem cells lacks of unique molecular markers. Thus, the exact number (rather 4 or 6 stem cells per crypt), location (either at position +4 relative to the crypt bottom, or hidden between Paneth cells and identified as crypt base columnar cells), and growth rate of intestinal stem cells is still unknown with certainty (Barker and Clevers, 2007).

The RNA binding protein Musashi-1, which expression in neonatal, adult, and regenerating mouse crypts is consistent with the predicted number and distribution of intestinal stem cells, has been proposed as a marker for stemness (Potten et al., 2003). However, among the potential stem cell markers, genes targeted by the Wnt signalling pathway may represent some of the best candidates. Indeed the Wnt/ β -catenin/T-Cell factor-lymphoid enhancing factor signalling pathway is the most dominant force in controlling cell fate along the crypt-villus axis and has been shown to specifically target the stem cell niche at the bottom of intestinal crypts, where the stem cells are located (Pinto and Clevers, 2005; Wong et al., 2002) (Fig. 2). Thus, Clevers and collaborators have conducted numerous studies to track down the stem cells of the intestine (Barker and Clevers, 2007). Recently,

they identified *Lgr5*, an orphan-protein coupled receptor as a marker of stem cells in mouse small intestine (Barker et al., 2007) sustaining the hypothesis of crypt base columnar cells as being the true stem cells.

As previously mentioned, several layers of molecular complexity drive the differentiation of stem cells. The signalling pathways and the numerous transcription factors involved in the elaboration of the four different cell lineages present in the intestine, and therefore in gut homeostasis, are now better understood and have recently been reviewed (Yen and Wright, 2006; de Santa Barbara et al., 2003; Radtke and Clevers, 2005; Leedham et al., 2005a; Buisine et al., 2008). The epigenetic rearrangements underlying expression of these differentiation factors, on the other hand, still need to be better characterized (Vincent and van Seuningen, 2008).

For this purpose the *Drosophila* seems to be an adequate animal model. A very recent study showed that *Drosophila* gene, *scrawny*, encoding a ubiquitin-specific protease, is required in intestinal stem cells, functions in gene silencing to deubiquitylate histone H2B, and represents a common mechanism within stem cells that is used to repress the premature expression of key differentiation genes, including Notch target genes (Buszczak et al., 2009).

On the other hand, the development of a reliable ex vivo model for mouse intestine differentiation by Tou and collaborators allowed these authors to investigate the functions of class I HDACs in mammalian intestine development and cytodifferentiation (Tou et al., 2004). In particular, they showed that HDAC1 and HDAC2 expression level decreased significantly upon tissue differentiation. HDAC3 (Wilson et al., 2006) and DNMT1 (De Marzo et al., 1999) harbour the same expression profile along the crypt-villus axis (Fig. 2). From this, one can speculate that activation of maturation-associated genes encoding intestine-specific markers is driven by acetylation of core histone proteins and demethylation at their promoters. Confirming this hypothesis, a recent study in rats showed that sucrose isomaltase, a marker of terminal differentiation of absorptive cells, was induced during the transition from the crypt to the villi by a switch in histone modifications at the promoter region from di- and trimethylated H3K9 to diacetylated H3K9/K14 (Suzuki et al., 2008) (Fig. 2).

Accordingly, numerous studies have shown the positive effect of Class I HDAC inhibition on expression of terminal differentiation markers in the intestine by using HDAC inhibitors (Fig. 2). Valproic acid has been shown to accelerate cytodifferentiation and activate the expression of intestinal markers such as apolipoprotein 1A, intestinal and liver fatty acid-binding proteins 1 and 2 (Tou et al., 2004), while sodium butyrate specifically induces the expression of absorptive cell markers, such as the mucin MUC3 and alkaline phosphatase (Velcich et al., 1995), to the detriment of secretory markers, such as trefoil factor 3 (TFF3) (Augenlicht et al., 2003). Our recent work showed that the effect of sodium butyrate on expression of the goblet cell marker mucin MUC2 is dose-dependent and is associated with increased acetylation of histones H3 and H4 and methylation of K4H3 at the promoter (Burger-van Paassen et al., 2009). Finally, trichostatin A increases significantly the expression of MUC2 in undifferentiated colonic cells (Vincent et al., 2007). HDAC3 gene silencing, on the other hand, induces expression of alkaline phosphatase in colon cancer cell lines (Wilson et al., 2006).

Furthermore, we recently demonstrated that MUC2 is silenced by DNA hypermethylation in colonic undifferentiated cells that undergo demethylation of MUC2 promoter once they reach confluence in culture and start differentiate. This finding led us to hypothesise that epigenetic silencing of MUC2 would be a mechanism used by intestinal stem cells not yet engaged in the differentiation process to maintain their undifferentiated state

(Vincent et al., 2007). Similarly, TFF3 gene has been shown to be repressed by methylation in organs that do not express this intestinal goblet cell marker (Ribieras et al., 2001), while cell differentiation-dependent epigenetic modifications at the 5'-UTR of the gene encoding the mucin MUC4, a differentiation marker of intestinal cells (Jonckheere et al., 2007), have been shown to occur in epithelial cancer cells (Vincent et al., 2008).

These studies confirm that epigenetic reprogramming occurs at genes encoding specific markers for the four types of mature cells in the gut, allowing their activation upon maturation of intestinal stem cells. Thus, chromatin modifier enzymes, may also represent good candidate markers for the identification of intestinal stem cells. Interestingly, *Bmi1*, a member of the PcG gene family part of the PcG-repressing Complex 1 already known to be involved in the self-renewal of neuronal, hematopoietic and leukemic cells, has been recently identified as an intestinal stem cell marker (Sangiorgi and Capecchi, 2008).

Other groups have shown that regulation of key developmental pathways is also ensured by chromatin modifier enzymes. In particular, the methylcytosine binding domain 2 (*mbd2*) regulates Wnt signalling and binds the *Lect2* promoter in association with NuRD (Phesse et al., 2008) (Fig. 2).

Conversely, while isolation of human intestinal SSCs is precluded, analysis of methylation patterns in human colonic or intestinal crypts has proven to help reveal niche characteristics (Kim et al., 2005b; Kim and Shibata, 2002; Nicolas et al., 2007). Search for methylation tags has also been a strategy to better determine stem cell number and how they divide in the crypt (Yatabe et al., 2001). The elegant tracing strategy adopted in these studies confirmed that (i) all epithelial cell types derive from a single stem cell, (ii) that crypts contain multiple stem cells and can multiply through lateral fission and (iii) that age-dependent methylation profiles are established in the intestinal crypts.

Thus, models and techniques used to isolate the intestinal crypts at different heights along the crypt-villus axis (Suzuki et al., 2008) and the recent identification of intestinal stem cell markers (Barker et al., 2007; Sangiorgi and Capecchi, 2008), coupled with new high throughput techniques aimed at studying epigenetic landscapes (methylated CpG island amplification (MCA), followed by hybridization on microarrays (Omura et al., 2008), methylated DNA immunoprecipitation (MeDIP)-on-chip (Keshet et al., 2006), or ultradeep bisulfite sequencing (Taylor et al., 2007)) will certainly bring new insights into the mechanisms of embryonic development and cell differentiation (Fig. 2).

Regarding miRNAs in intestinal stem cells, not much is known but overlapping miRNA profiles between normal intestinal cell and colon cancer cells indicated that miRNA mi-R-17-92 and its target E2F1 may play a role in colonic crypt cell transformation into cancer cell. Enrichment of miRNA mi-R-17-5p was also found in the proliferating crypt compartment (Monzo et al., 2008). Some miRNAs are also induced by transcription factors responsible for intestinal cell differentiation (Hino et al., 2008). Much more work is surely needed to identify pattern of miRNA expression and their involvement in neoplastic transformation of the colonic epithelium.

5. Abnormal epigenetic reprogramming, carcinogenesis and cancer stem cells

Because ESCs share certain characteristics with cancer cells (lack of senescence, regulation of cell cycle, and contact inhibition) and altered patterns of epigenetic modifications observed in cancer cells are sometimes reminiscent from early embryonic development, deciphering the mechanisms of establishment of epigenetic marks in the genome could help understand the

1 process of dedifferentiation undergone by normal cells during
early steps of carcinogenesis (Fig. 2).

3 Indeed, repressive chromatin marks associated with the
promoters of silenced genes in cancer cells resemble the
5 chromatin modifications inherent to those same genes in normal
stem cells. In particular, bivalent chromatin marks specific for
7 ESCs are often found at genes epigenetically silenced in cancer
cells and may predispose these tumour suppressor genes to
9 hypermethylation (Ohm et al., 2007).

11 Methylation and histone modification profiles of SSCs, how-
ever, are significantly different from ESCs, differentiated cells and
from cancer cells (Bibikova et al., 2006), the latest being
13 characterized by an added layer of complexity (Ohm et al.,
2007). Although only a small number of CpGs contributes to this
15 difference, the methylation pattern of a small number of
developmentally **controlled** genes may constitute a useful epige-
17 netic mark, unique for each type of cells, and may help distinguish
between normal and cancer cells in the early events of
19 carcinogenesis. Moreover, it suggests that if stem cells do not
respond properly to the differentiation signal and do not direct the
21 appropriate epigenetic rearrangements, they may proliferate
wildly, resulting in cancer. This statement has been extensively
23 studied at the genetic and transcriptional level in the gut, where it
is thought that uncontrolled stem cells are the initiators of
25 gastrointestinal cancers (Leedham et al., 2005b; Barker et al.,
2009), and has been recently confirmed as Lgr5 expression
27 pattern, the recently highlighted marker of intestinal stem cells,
in mouse and human adenomas resembles its expression pattern
29 in the normal intestinal crypts (Becker et al., 2008; Barker et al.,
2009). Similarly, over-**expression** of Bmi1, the other intestinal SSC
31 marker, has been correlated with the malignant grades of human
digestive precancerous tissues, which suggests that advanced
33 Bmi1 dysregulation might predict malignant progression (Tateishi
et al., 2006).

35 The hypothesis of crypt stem cells being the cells-of-origin of
intestinal cancer is further supported by epigenetic evidence. In
37 particular, misexpression of numerous Wnt signalling pathway
antagonists has been attributed to changes in the methylation
39 profile of the genes. For instance, silencing of **adenomatous**
polyposis coli (APC) gene has been found in colorectal cancers
41 (van der Flier and Clevers, 2008) and has been associated with
promoter hypermethylation (Esteller et al., 2000), even though
43 APC promoter hypermethylation alone does not seem to result in
complete gene inactivation (Segditsas et al., 2008). Similarly,
45 **secreted** frizzled-related proteins (SFRPs), identified and reported
to act as inhibitors of the Wnt signalling pathway, are hyper-
47 methylated in microsatellite unstable colorectal cancers (Tanaka
et al., 2008). Moreover, methylation of APC1A, APC2, SFRP1, and
49 SFRP2 appears to mark progression from colitis inflammatory
bowel disease to inflammatory bowel disease-associated neoplasia,
51 and these genes may serve as biomarkers for this disease (Dhir
et al., 2008). SOX7, a suppressor of **β-catenin-mediated** transcrip-
53 tional activity was also found to be silenced by methylation in
human colorectal cancer cell lines (Zhang et al., 2008). Along with
55 changes in methylation profiles, members of the Wnt signalling
pathway undergo dramatic changes in chromatin marks in colon
57 cancer. HDAC3 over-expression in half of colon adenocarcinomas
favour **β-catenin** translocation to the nucleus and inhibits three
59 known Wnt inhibitors, namely TLE1, TLE4 and SMO (Godman et
al., 2008).

61 Along with the Wnt signalling pathway, the **bone morphogenic**
proteins (BMPs), members of the TGF β growth factor superfamily,
63 have well-described roles in the **crypt-villus** axis development
where BMP-4 functions as a negative regulator of intestinal stem
65 cell proliferation (Yen and Wright, 2006). Disrupted BMP signal-
ing and a role for BMP3 in colorectal cancer in tumour

development has recently been investigated. Indeed, BMP3 has
been found to be down-regulated in colorectal cancer by extensive
67 hypermethylation correlated with microsatellite instability and
the CpG **island methylator** (Loh et al., 2008). 69

71 In addition, cancer cells undergo epigenetic changes through-
out the differentiation pathway, inducing the silencing of markers
of terminal differentiation as well as transcription factors involved
73 in their expression. In particular, p16 (Lee et al., 2006), CDX-2
(Kawai et al., 2005) or GATA-4/-5 (Akiyama et al., 2003)
75 transcription factors are silenced by promoter hypermethylation
or by PcG proteins in colorectal cancer (Visvader and Lindeman,
2008). We and others have shown that MUC2 gene, which
77 encodes a secreted mucin and intestinal goblet cell marker, is
silenced by hypermethylation and histone deacetylation in color-
79 ectal cancers (Vincent et al., 2007; Gratchev et al., 2001). By
genome-wide search, other genes encoding terminal differentia-
81 tion markers, such as the enteroendocrine cell markers somatos-
tatin and Tachykinin-1, were also found to be epigenetically
83 silenced in colon cancer (Mori et al., 2006). Thus, this epigenetic
mechanism locks the entire signalling cascade responsible for
85 differentiation, ensuring that cancer cells maintain their undiffer-
entiated state and their proliferative skills. 87

89 Tumours harbour stem cell population markers, such as CD133
(encoded by the PROM1 gene), CD44 or EpCAM (epithelial cell
adhesion molecule) in colorectal cancer (Visvader and Lindeman,
2008). They have heterogeneous cell population among which
91 only cell subsets have the capacity to regenerate a tumour, and are
driven by the upregulation of pathways essential for maintenance
93 of stem cells, such as the Wnt/ β -catenin pathway (Humphries and
Wright, 2008), while genes involved in cell differentiation, are
95 silenced by promoter hypermethylation or by PcG proteins. Thus,
it has been suggested that stem cells or early progenitor cells may
97 be the precursors of “cancer stem cells” (Visvader and Lindeman,
2008). The discussion about the existence and significance of the
99 cancer stem cell, opposing to the clonal evolution model of a
tumour, has been going on since the concept was proposed. 101
Cancer stem cells are supposed to be the root of tumour
103 recurrence and metastasis, i.e. cells within a tumour that possess
the capacity to reform tumours with all its heterogeneity (Fodde,
105 2009). However, cancer stem cells are difficult to isolate and
therefore still have to be characterized, especially in solid
107 tumours, where specific markers still need to be found. For these
reasons, understanding the epigenetic mechanisms driving (de)d-
109 ifferentiation of stem cells is crucial. In this regard, it has been
proposed that investigating miRNAs, expressed as specific sets in
111 normal stem cells and playing an important role in maintenance
of their **self-renewal** capacity, would be of great interest for
elucidating characteristics of cancer stem cells (Xia, 2008). 112

6. Concluding remarks 114

115 Although most of embryogenesis studies have focused on
genetic and transcriptional regulation, epigenetic programming is
a crucial step during development and differentiation in mam-
116 mals and deserves particular attention in a way to better
understand the mechanisms underlying occurrence of severe
117 diseases, including cancer. While serious ethical issues are related
to the use of human ESCs, researchers have developed parades and
118 alternative methods to be able to study differentiation mechan-
isms. Among them, nuclear transfer, altered nuclear transfer, and
119 parthenogenesis bring their own set of advantages and disadvan-
tages (Kastenberger and Odorico, 2008). This review focused on
120 adult intestinal niches as a model of choice in which stem/
progenitor cells are localized in the crypts, a well-identified
structure that can be isolated for various types of studies in vitro,

in vivo and in silico. Indeed, mathematical models including cell proliferation, migration, differentiation, crypt fission, genetic instability, APC inactivation and tumour heterogeneity may also help biologists better understand stem cell dynamics (Ro and Rannala, 2001) and how stem cells of the crypt system and colon carcinogenesis function and derive from each other (van Leeuwen et al., 2006; Johnston et al., 2007).

Genetic and epigenetic reprogramming of signals involved in development and differentiation frequently occurs in cancer and has major implication for diagnosis, prognosis, and treatment. Indeed, the pathways that are involved in cell differentiation are commonly impaired, especially in gastrointestinal cancers (Fodde, 2009; Bach et al., 2000). The very first step of carcinogenesis still has to be identified with certainty but some clues have been brought by recent studies showing age-related methylation and chromatin remodelling in small intestine (Kim et al., 2005b; Kirkwood, 2004; Martin et al., 1998). Moreover, epigenetic profiles including miRNAs, which already helped identify stem cells, will surely lift the veil concerning the controversial concept of cancer stem cells.

The discovery of epigenetic differentiation programming of in cancer gave rise to new treatment strategies, as this mechanism of gene silencing is reversible. Indeed, pharmacological inhibitors of class I and II HDAC activity have been identified as potent inducers of growth arrest, differentiation and apoptosis of colon cancer cells in vitro and in vivo (Mariadason, 2008). Interestingly, epigenetic remodelling, as a precursor event of gastrointestinal cancers, raises the possibility of cancer prevention by an adequate diet. In particular, dietary HDAC inhibitors have been identified in cruciferous vegetables, such as broccoli (Dashwood and Ho, 2007). However, neo-adjuvant therapy in cancer does not seem to be able to modify crypt methylation pattern, which suggests that stem cells are relatively protected from transient environment changes (Kim et al., 2005a).

Inflammatory bowel diseases such as ulcerative colitis and Crohn's disease as a risk to develop colorectal cancer for the patient occurs in 5% of the cases. A recent study showed that methylation may link both situations with inflammatory gut leading to a new aberrant DNA methylation signature also observed later in carcinogenesis (Hahn et al., 2008). Interestingly this mechanism is mediated by PcG complex, known to play a crucial role in cell differentiation during development. Modifications of the methylation pattern may also be involved in polyclonal disorders as a switch between preneoplastic stages and progression toward carcinoma. It was recently shown that in non-inherited polyclonal disorders such as gastric cancers associated with intestinal metaplasia an independent aberrant methylation of multiple genes characterized metaplastic glands that later may become cancerous (Mihara et al., 2006).

Finally, epigenetically induced pluripotency may help stem cell research for the elaboration of new hopeful treatments for various neurodegenerative diseases such as Parkinson's disease (Xi and Zhang, 2008), amyotrophic lateral sclerosis, Alzheimer's disease or Huntington's disease (Hou and Hong, 2008), as well as autoimmune diseases such as multiple sclerosis (Mancardi and Saccardi, 2008), spinal cord injuries (Amoh et al., 2008), and muscle damage (Sharma and Raghbir, 2007) by cell transplantation therapies.

References

Agger, K., Christensen, J., Cloos, P.A., Helin, K., 2008. The emerging functions of histone demethylases. *Curr. Opin. Genet. Dev.* 18, 159–168.
 Akiyama, Y., Watkins, N., Suzuki, H., Jair, K.W., van Engeland, M., Esteller, M., Sakai, H., Ren, C.Y., Yuasa, Y., Herman, J.G., Baylin, S.B., 2003. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes

are epigenetically silenced in colorectal and gastric cancer. *Mol. Cell Biol.* 23, 8429–8439.
 Amoh, Y., Li, L., Katsuoka, K., Hoffman, R.M., 2008. Multipotent hair follicle stem cells promote repair of spinal cord injury and recovery of walking function. *Cell Cycle* 7, 1865–1869.
 Augenlicht, L., Shi, L., Mariadason, J., Laboisse, C., Velcich, A., 2003. Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. *Oncogene* 22, 4983–4992.
 Bach, S.P., Renehan, A.G., Potten, C.S., 2000. Stem cells: the intestinal stem cell as a paradigm. *Carcinogenesis* 21, 469–476.
 Balhorn, R., 2007. The protamine family of sperm nuclear proteins. *Genome Biol.* 8, 227.
 Bannister, A.J., Zegerman, P., Partridge, J.F., Miska, E.A., Thomas, J.O., Allshire, R.C., Kouzarides, T., 2001. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature* 410, 120–124.
 Barker, N., Clevers, H., 2007. Tracking down the stem cells of the intestine: strategies to identify adult stem cells. *Gastroenterology* 133, 1755–1760.
 Barker, N., Ridgway, R.A., van Es, J.H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A.R., Sansom, O.J., Clevers, H., 2009. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 457, 608–611.
 Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P.J., Clevers, H., 2007. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 449, 1003–1007.
 Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297.
 Becker, L., Huang, Q., Mashimo, H., 2008. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. *Sci. World J.* 8, 1168–1176.
 Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., Jaenisch, R., Wagschal, A., Feil, R., Schreiber, S.L., Lander, E.S., 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* 125, 315–326.
 Bibikova, M., Chudin, E., Wu, B., Zhou, L., Garcia, E.W., Liu, Y., Shin, S., Plaia, T.W., Auerbach, J.M., Arking, D.E., Gonzalez, R., Crook, J., Davidson, B., Schulz, T.C., Robins, A., Khanna, A., Sartipy, P., Hyllner, J., Vanguri, P., Savant-Bhonsale, S., Smith, A.K., Chakravarti, A., Maitra, A., Rao, M., Barker, D.L., Loring, J.F., Fan, J.B., 2006. Human embryonic stem cells have a unique epigenetic signature. *Genome Res.* 16, 1075–1083.
 Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H., Helin, K., 2006. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. *Genes Dev.* 20, 1123–1136.
 Buisine, M.P., Porchet, N., Van Seuningen, I., 2008. Mucin expression and regulation during development and cell differentiation. In: van Seuningen, I. (Ed.), *The Epithelial Mucins: Structure/Function. Roles in Cancer and Inflammatory Diseases*. Research Signpost, Kerala, pp. 75–94.
 Burger-van Paassen, N., Vincent, A., Puiiman, P.J., van der Sluis, M., Bouma, J., Boehm, G., van Goudoever, J.B., Van Seuningen, I., Renes, I.B., 2009. The regulation of the intestinal mucin MUC2 expression by short chain fatty acids: implications for epithelial protection. *Biochem. J.*
 Buszczak, M., Paterno, S., Spradling, A.C., 2009. Drosophila stem cells share a common requirement for the histone H2B ubiquitin protease scrawny. *Science* 323, 248–251.
 Calin, G.A., Croce, C.M., 2006. MicroRNA signatures in human cancers. *Nat. Rev. Cancer* 6, 857–866.
 Cano-Gauci, D.F., Luaili, J.C., Ouellette, A.J., Brady, G., Iscove, N.N., Buick, R.N., 1993. In vitro cDNA amplification from individual intestinal crypts: a novel approach to the study of differential gene expression along the crypt-villus axis. *Exp. Cell Res.* 208, 344–349.
 Chen, L., Daley, G.Q., 2008. Molecular basis of pluripotency. *Hum. Mol. Genet.* 17, R23–R27.
 Collas, P., Noer, A., Timoskainen, S., 2007. Programming the genome in embryonic and somatic stem cells. *J. Cell Mol. Med.* 11, 602–620.
 Crosnier, C., Stamataki, D., Lewis, J., 2006. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. *Nat. Rev. Genet.* 7, 349–359.
 Dashwood, R.H., Ho, E., 2007. Dietary histone deacetylase inhibitors: from cells to mice to man. *Semin. Cancer Biol.* 17, 363–369.
 De Marzo, A.M., Marchi, V.L., Yang, E.S., Veeraswamy, R., Lin, X., Nelson, W.G., 1999. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. *Cancer Res.* 59, 3855–3860.
 de Santa Barbara, P., van den Brink, G.R., Roberts, D.J., 2003. Development and differentiation of the intestinal epithelium. *Cell Mol. Life Sci.* 60, 1322–1332.
 Dhir, M., Montgomery, E.A., Glockner, S.C., Schuebel, K.E., Hooker, C.M., Herman, J.G., Baylin, S.B., Gearhart, S.L., Ahuja, N., 2008. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. *J. Gastrointest Surg.* 12, 1745–1753.
 Esteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M.A., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S.J., Baylin, S.B., Herman, J.G., 2000. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. *Cancer Res.* 60, 4366–4371.
 Fodde, R., 2009. The stem of cancer. *Cancer Cell* 15, 87–89.
 Fodde, R., Brabletz, T., 2007. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. *Curr. Opin. Cell Biol.* 19, 150–158.
 Fulka, H., St John, J.C., Fulka, J., Hozak, P., 2008. Chromatin in early mammalian embryos: achieving the pluripotent state. *Differentiation* 76, 3–14.

- 1 Godman, C.A., Joshi, R., Tierney, B.R., Greenspan, E., Rasmussen, T.P., Wang, H.W.,
2 Shin, D.G., Rosenberg, D.W., Giardina, C., 2008. HDAC3 impacts multiple
3 oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D
4 signaling. *Cancer Biol. Ther.* 7, 1570–1580.
- 5 Gonzalez, S., Pisano, D.G., Serrano, M., 2008. Mechanistic principles of chromatin
6 remodeling guided by siRNAs and miRNAs. *Cell Cycle* 7, 2601–2608.
- 7 Gratchev, A., Siedow, A., Bumke-Vogt, C., Hummel, M., Foss, H.D., Hanski, M.L.,
8 Kobalz, U., Mann, B., Lammert, H., Humsmann, U., Stein, H., Riecken, E.O.,
9 Hanski, C., 2001. Regulation of the intestinal mucin MUC2 gene expression in
10 vivo: evidence for the role of promoter methylation. *Cancer Lett.* 168, 71–80.
- 11 Grossmann, J., Maxson, J.M., Whitacre, C.M., Orosz, D.E., Berger, N.A., Fiocchi, C.,
12 Levine, A.D., 1998. New isolation technique to study apoptosis in human
13 intestinal epithelial cells. *Am. J. Pathol.* 153, 53–62.
- 14 Hahn, M.A., Hahn, T., Lee, D.H., Esworthy, R.S., Kim, B.W., Riggs, A.D., Chu, F.F.,
15 Pfeifer, G.P., 2008. Methylation of polycomb target genes in intestinal cancer is
16 mediated by inflammation. *Cancer Res.* 68, 10280–10289.
- 17 Hattori, N., Shiota, K., 2008. Epigenetics: the study of embryonic stem cells by
18 restriction landmark genomic scanning. *FEBS J.* 275, 1624–1630.
- 19 He, L., Hannon, G.J., 2004. MicroRNAs: small RNAs with a big role in gene
20 regulation. *Nat. Rev. Genet.* 5, 522–531.
- 21 Heby, O., 1995. DNA methylation and polyamines in embryonic development and
22 cancer. *Int. J. Dev. Biol.* 39, 737–757.
- 23 Hino, K., Tsuchiya, K., Fukao, T., Kiga, K., Okamoto, R., Kanai, T., Watanabe, M., 2008.
24 Inducible expression of microRNA-194 is regulated by HNF-1alpha during
25 intestinal epithelial cell differentiation. *RNA* 14, 1433–1442.
- 26 Hou, L., Hong, T., 2008. Stem cells and neurodegenerative diseases. *Sci. China C Life
27 Sci.* 51, 287–294.
- 28 Houbaviy, H.B., Murray, M.F., Sharp, P.A., 2003. Embryonic stem cell-specific
29 MicroRNAs. *Dev. Cell* 5, 351–358.
- 30 Humphries, A., Wright, N.A., 2008. Colonic crypt organization and tumorigenesis.
31 *Nat. Rev. Cancer* 8, 415–424.
- 32 Jackson, M., Krassowska, A., Gilbert, N., Chevassut, T., Forrester, L., Ansell, J.,
33 Ramsahoye, B., 2004. Severe global DNA hypomethylation blocks differentiation
34 and induces histone hyperacetylation in embryonic stem cells. *Mol. Cell
35 Biol.* 24, 8862–8871.
- 36 Johnston, M.D., Edwards, C.M., Bodmer, W.F., Maini, P.K., Chapman, S.J., 2007.
37 Mathematical modeling of cell population dynamics in the colonic crypt and in
38 colorectal cancer. *Proc. Natl. Acad. Sci. USA* 104, 4008–4013.
- 39 Jonckheere, N., Vincent, A., Perrais, M., Ducourouble, M.P., Male, A.K., Aubert, J.P.,
40 Pigny, P., Carraway, K.L., Freund, J.N., Renes, I.B., Van Seuning, I., 2007. The
41 human mucin MUC4 is transcriptionally regulated by caudal-related homeo-
42 box, hepatocyte nuclear factors, forkhead box A, and GATA endodermal
43 transcription factors in epithelial cancer cells. *J. Biol. Chem.* 282, 22638–22650.
- 44 Kastenberg, Z.J., Odorico, J.S., 2008. Alternative sources of pluripotency: science,
45 ethics, and stem cells. *Transplant Rev. (Orlando)* 22, 215–222.
- 46 Kawai, H., Tomii, K., Toyooka, S., Yano, M., Murakami, M., Tsukuda, K., Shimizu, N.,
47 2005. Promoter methylation downregulates CDX2 expression in colorectal
48 carcinomas. *Oncol. Rep.* 13, 547–551.
- 49 Keshet, I., Schlesinger, Y., Farkash, S., Rand, E., Hecht, M., Segal, E., Pikarski, E.,
50 Young, R.A., Niveleau, A., Cedar, H., Simon, I., 2006. Evidence for an instructive
51 mechanism of de novo methylation in cancer cells. *Nat. Genet.* 38, 149–153.
- 52 Kim, J.Y., Beart, R.W., Shibata, D., 2005a. Stability of colon stem cell methylation
53 after neo-adjuvant therapy in a patient with attenuated familial adenomatous
54 polyposis. *BMC Gastroenterol.* 5, 19.
- 55 Kim, J.Y., Siegmund, K.D., Tavare, S., Shibata, D., 2005b. Age-related human small
56 intestine methylation: evidence for stem cell niches. *BMC Med.* 3, 10.
- 57 Kim, K.M., Shibata, D., 2002. Methylation reveals a niche: stem cell succession in
58 human colon crypts. *Oncogene* 21, 5441–5449.
- 59 Kirkwood, T.B., 2004. Intrinsic ageing of gut epithelial stem cells. *Mech. Ageing
60 Dev.* 125, 911–915.
- 61 Klose, R.J., Zhang, Y., 2007. Regulation of histone methylation by demethylimination
62 and demethylation. *Nat. Rev. Mol. Cell Biol.* 8, 307–318.
- 63 Lagarkova, M.A., Volchkov, P.Y., Lyakishcheva, A.V., Philonenko, E.S., Kiselev, S.L.,
64 2006. Diverse epigenetic profile of novel human embryonic stem cell lines. *Cell
65 Cycle* 5, 416–420.
- 66 Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G.,
67 Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., Seiser, C., 2002.
68 Essential function of histone deacetylase 1 in proliferation control and CDK
69 inhibitor repression. *EMBO J.* 21, 2672–2681.
- 70 Lee, M., Sup Han, W., Kyoung Kim, O., Hee Sung, S., Sun Cho, M., Lee, S.N., Koo, H.,
71 2006. Prognostic value of p16INK4a and p14ARF gene hypermethylation in
72 human colon cancer. *Pathol. Res. Pract.* 202, 415–424.
- 73 Leedham, S.J., Brittan, M., McDonald, S.A., Wright, N.A., 2005a. Intestinal stem
74 cells. *J. Cell Mol. Med.* 9, 11–24.
- 75 Leedham, S.J., Thliveris, A.T., Halberg, R.B., Newton, M.A., Wright, N.A., 2005b.
76 Gastrointestinal stem cells and cancer: bridging the molecular gap. *Stem Cell
77 Rev.* 1, 233–241.
- 78 Lengner, C.J., Camargo, F.D., Hochedlinger, K., Welstead, G.G., Zaidi, S., Gokhale, S.,
79 Scholer, H.R., Tomilin, A., Jaenisch, R., 2007. Oct4 expression is not required for
80 mouse somatic stem cell self-renewal. *Cell Stem Cell* 1, 403–415.
- 81 Li, E., Bestor, T.H., Jaenisch, R., 1992. Targeted mutation of the DNA methyl-
82 transferase gene results in embryonic lethality. *Cell* 69, 915–926.
- 83 Liang, J., Wan, M., Zhang, Y., Gu, P., Xin, H., Jung, S.Y., Qin, J., Wong, J., Cooney, A.J.,
84 Liu, D., Songyang, Z., 2008. Nanog and Oct4 associate with unique transcrip-
85 tional repression complexes in embryonic stem cells. *Nat. Cell Biol.* 10,
86 731–739.
- 87 Loh, K., Chia, J.A., Greco, S., Cozzi, S.J., Buttenshaw, R.L., Bond, C.E., Simms, L.A., Pike,
88 T., Young, J.P., Jass, J.R., Spring, K.J., Leggett, B.A., Whitehall, V.L., 2008. Bone
89 morphogenic protein 3 inactivation is an early and frequent event in colorectal
90 cancer development. *Genes Chromosomes Cancer* 47, 449–460.
- 91 Loh, Y.H., Zhang, W., Chen, X., George, J., Ng, H.H., 2007. Jmjd1a and Jmjd2c histone
92 H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. *Genes
93 Dev.* 21, 2545–2557.
- 94 Lunyak, V.V., Rosenfeld, M.G., 2008. Epigenetic regulation of stem cell fate. *Hum.
95 Mol. Genet.* 17, R28–R36.
- 96 Mancardi, G., Saccardi, R., 2008. Autologous haematopoietic stem-cell transplan-
97 tation in multiple sclerosis. *Lancet Neurol.* 7, 626–636.
- 98 Mariadason, J.M., 2008. HDACs and HDAC inhibitors in colon cancer. *Epigenetics* 3,
99 28–37.
- 100 Marshman, E., Booth, C., Potten, C.S., 2002. The intestinal epithelial stem cell.
101 *Bioessays* 24, 91–98.
- 102 Martin, K., Kirkwood, T.B., Potten, C.S., 1998. Age changes in stem cells of murine
103 small intestinal crypts. *Exp. Cell Res.* 241, 316–323.
- 104 Mihara, M., Yoshida, Y., Tsukamoto, T., Inada, K., Nakanishi, Y., Yagi, Y., Imai, K.,
105 Sugimura, T., Tatematsu, M., Ushijima, T., 2006. Methylation of multiple genes
106 in gastric glands with intestinal metaplasia: a disorder with polyclonal origins.
107 *Am. J. Pathol.* 169, 1643–1651.
- 108 Monk, M., Boubelik, M., Lehnert, S., 1987. Temporal and regional changes in DNA
109 methylation in the embryonic, extraembryonic and germ cell lineages during
110 mouse embryo development. *Development* 99, 371–382.
- 111 Monzo, M., Navarro, A., Bandres, E., Artells, R., Moreno, I., Gel, B., Ibeas, R., Moreno,
112 J., Martinez, F., Diaz, T., Martinez, A., Balague, O., Garcia-Foncillas, J., 2008.
113 Overlapping expression of microRNAs in human embryonic colon and color-
114 ectal cancer. *Cell Res.* 18, 823–833.
- 115 Mori, Y., Cai, K., Cheng, Y., Wang, S., Paun, B., Hamilton, J.P., Jin, Z., Sato, F., Berki,
116 A.T., Kan, T., Ito, T., Mantzur, C., Abraham, J.M., Meltzer, S.J., 2006. A genome-
117 wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5
118 other genes in colon cancer. *Gastroenterology* 131, 797–808.
- 119 Nicolas, P., Kim, K.M., Shibata, D., Tavare, S., 2007. The stem cell population of the
120 human colon crypt: analysis via methylation patterns. *PLoS Comput. Biol.* 3,
121 e28.
- 122 O'Shea, K.S., 2004. Self-renewal vs. differentiation of mouse embryonic stem cells.
123 *Biol. Reprod.* 71, 1755–1765.
- 124 Ohm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L., Mohammad,
125 H.P., Chen, W., Daniel, V.C., Yu, W., Berman, D.M., Jenuwein, T., Pruitt, K.,
126 Sharkis, S.J., Watkins, D.N., Herman, J.G., Baylin, S.B., 2007. A stem cell-like
127 chromatin pattern may predispose tumor suppressor genes to DNA hyper-
128 methylation and heritable silencing. *Nat. Genet.* 39, 237–242.
- 129 Okano, M., Bell, D.W., Haber, D.A., Li, E., 1999. DNA methyltransferases Dnmt3a and
130 Dnmt3b are essential for de novo methylation and mammalian development. *Cell*
131 99, 247–257.
- 132 Omura, N., Li, C.P., Li, A., Hong, S.M., Walter, K., Jimeno, A., Hidalgo, M., Goggins, M.,
133 2008. Genome-wide profiling of methylated promoters in pancreatic adeno-
134 carcinoma. *Cancer Biol. Ther.* 7, 1146–1156.
- 135 Pasini, D., Bracken, A.P., Hansen, J.B., Capillo, M., Helin, K., 2007. The polycomb
136 group protein Suz12 is required for embryonic stem cell differentiation. *Mol.
137 Cell Biol.* 27, 3769–3779.
- 138 Pheasant, T.J., Parry, L., Reed, K.R., Ewan, K.B., Dale, T.C., Sansom, O.J., Clarke, A.R.,
139 2008. Deficiency of Mbd2 attenuates Wnt signaling. *Mol. Cell Biol.* 28,
140 6094–6103.
- 141 Pinto, D., Clevers, H., 2005. Wnt, stem cells and cancer in the intestine. *Biol. Cell* 97,
142 185–196.
- 143 Potten, C.S., Booth, C., Tudor, G.L., Booth, D., Brady, G., Hurley, P., Ashton, G., Clarke,
144 R., Sakakibara, S., Okano, H., 2003. Identification of a putative intestinal stem
145 cell and early lineage marker; musashi-1. *Differentiation* 71, 28–41.
- 146 Radtke, F., Clevers, H., 2005. Self-renewal and cancer of the gut: two sides of a coin.
147 *Science* 307, 1904–1909.
- 148 Ribieras, S., Lefebvre, O., Tomasetto, C., Rio, M.C., 2001. Mouse Trefoil factor genes:
149 genomic organization, sequences and methylation analyses. *Gene* 266, 67–75.
- 150 Ro, S., Rannala, B., 2001. Methylation patterns and mathematical models reveal
151 dynamics of stem cell turnover in the human colon. *Proc. Natl. Acad. Sci. USA*
152 98, 10519–10521.
- 153 Robertson, K.D., 2005. DNA methylation and human disease. *Nat. Rev. Genet.* 6,
154 597–610.
- 155 Russo, V.E.A., Martienssen, R.A., Riggs, A.D., 1996. *Epigenetic Mechanisms of Gene
156 Regulation*. Cold Spring Harbor Laboratory Press, New York.
- 157 Rybak, A., Fuchs, H., Smirnova, L., Brandt, C., Pohl, E.E., Nitsch, R., Wulczyn, F.G.,
158 2008. A feedback loop comprising lin-28 and let-7 controls pre-let-7
159 maturation during neural stem-cell commitment. *Nat. Cell Biol.* 10, 987–993.
- 160 Sangiorgi, E., Capecchi, M.R., 2008. Bmi1 is expressed in vivo in intestinal stem
161 cells. *Nat. Genet.* 40, 915–920.
- 162 Santos-Rosa, H., Caldas, C., 2005. Chromatin modifier enzymes, the histone code
163 and cancer. *Eur. J. Cancer* 41, 2381–2402.
- 164 Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J.,
165 Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E., Bergman, Y., Simon, I.,
166 Cedar, H., 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-
167 marks genes for de novo methylation in cancer. *Nat. Genet.* 39, 232–236.
- 168 Scoville, D.H., Sato, T., He, X.C., Li, L., 2008. Current view: intestinal stem cells and
169 signaling. *Gastroenterology* 134, 849–864.
- 170 Segditsas, S., Sieber, O.M., Rowan, A., Setien, F., Neale, K., Phillips, R.K., Ward, R.,
171 Esteller, M., Tomlinson, I.P., 2008. Promoter hypermethylation leads to
172 decreased APC mRNA expression in familial polyposis and sporadic colorectal

- 1 tumours, but does not substitute for truncating mutations. *Exp. Mol. Pathol.* 85, 201–206. 35
- 3 Sharma, R., Raghurir, R., 2007. Stem cell therapy: a hope for dying hearts. *Stem Cells Dev.* 16, 517–536. 37
- 5 Shen, X., Liu, Y., Hsu, Y.J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.C., Orkin, S.H., 2008. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. *Mol. Cell* 32, 491–502. 39
- 7 Suzuki, T., Mochizuki, K., Goda, T., 2008. Histone H3 modifications and Cdx-2 binding to the sucrase-isomaltase (SI) gene is involved in induction of the gene in the transition from the crypt to villus in the small intestine of rats. *Biochem. Biophys. Res. Commun.* 369, 788–793. 41
- 9 Tanaka, J., Watanabe, T., Kanazawa, T., Tada, T., Kazama, Y., Tanaka, T., Nagawa, H., 2008. Silencing of secreted frizzled-related protein genes in MSI colorectal carcinogenesis. *Hepatogastroenterology* 55, 1265–1268. 43
- 11 Tateishi, K., Ohta, M., Kanai, F., Guleng, B., Tanaka, Y., Asaoka, Y., Tada, M., Seto, M., Jazag, A., Lianjie, L., Okamoto, M., Isayama, H., Yoshida, H., Kawabe, T., Omata, M., 2006. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. *Clin. Cancer Res.* 12, 6960–6966. 45
- 13 Taylor, K.H., Kramer, R.S., Davis, J.W., Guo, J., Duff, D.J., Xu, D., Caldwell, C.W., Shi, H., 2007. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. *Cancer Res.* 67, 8511–8518. 47
- 15 Tou, L., Liu, Q., Shivdasani, R.A., 2004. Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. *Mol. Cell Biol.* 24, 3132–3139. 49
- 17 van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.P., Tjon-Pon-Fong, M., Moerer, P., van den Born, M., Soete, G., Pals, S., Eilers, M., Medema, R., Clevers, H., 2002. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* 111, 241–250. 51
- 19 van der Flier, L.G., Clevers, H., 2008. **Stem cells, self-renewal, and differentiation in the intestinal epithelium.** *Annu. Rev. Physiol.* 53
- 21 van Es, J.H., van Gijn, M.E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M., Robine, S., Winton, D.J., Radtke, F., Clevers, H., 2005. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. *Nature* 435, 959–963. 55
- 23 van Leeuwen, I.M., Byrne, H.M., Jensen, O.E., King, J.R., 2006. Crypt dynamics and colorectal cancer: advances in mathematical modelling. *Cell Prolif.* 39, 157–181. 57
- 25 Velcich, A., Palumbo, L., Jarry, A., Laboisie, C., Racevskis, J., Augenlicht, L., 1995. Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT29 colon carcinoma cells. *Cell Growth Differ* 6, 749–757. 59
- 27 Vincent, A., Ducourouble, M.P., Van Seuningen, I., 2008. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. *FASEB J.* 22, 3035–3045. 61
- 29 Vincent, A., Perrais, M., Desseyn, J.L., Aubert, J.P., Pigny, P., Van Seuningen, I., 2007. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. *Oncogene* 26, 6566–6576. 63
- 31 Vincent, A., van Seuningen, I., 2008. Mucins, epigenetics and cancer. In: van Seuningen, I. (Ed.), *The epithelial mucins: structure/function. Roles in cancer and inflammatory diseases.* Research Signpost, Kerala, pp. 95–108. 65
- 33 Visvader, J.E., Lindeman, G.J., 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat. Rev. Cancer* 8, 755–768. 67
- Walker, M.R., Stappenbeck, T.S., 2008. Deciphering the 'black box' of the intestinal stem cell niche: taking direction from other systems. *Curr. Opin. Gastroenterol.* 24, 115–120. 69
- Wen, B., Wu, H., Shinkai, Y., Irizarry, R.A., Feinberg, A.P., 2009. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. *Nat. Genet.* 41, 246–250. 71
- Wilson, A.J., Byun, D.S., Popova, N., Murray, L.B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L.H., Mariadason, J.M., 2006. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. *J. Biol. Chem.* 281, 13548–13558. 73
- Wong, M.H., Huelsken, J., Birchmeier, W., Gordon, J.I., 2002. Selection of multipotent stem cells during morphogenesis of small intestinal crypts of Lieberkuhn is perturbed by stimulation of Lef-1/beta-catenin signaling. *J. Biol. Chem.* 277, 15843–15850. 75
- Xi, J., Zhang, S.C., 2008. Stem cells in development of therapeutics for Parkinson's disease: a perspective. *J. Cell Biochem.* 105, 1153–1160. 77
- Xia, M.H.P., 2008. Great potential of MicroRNA in cancer stem cell. *J. Cancer Mol.* 4, 79–89. 79
- Yatabe, Y., Tavare, S., Shibata, D., 2001. Investigating stem cells in human colon by using methylation patterns. *Proc. Natl. Acad. Sci. USA* 98, 10839–10844. 81
- Yen, T.H., Wright, N.A., 2006. The gastrointestinal tract stem cell niche. *Stem Cell Rev.* 2, 203–212. 83
- Yeo, S., Jeong, S., Kim, J., Han, J.S., Han, Y.M., Kang, Y.K., 2007. Characterization of DNA methylation change in stem cell marker genes during differentiation of human embryonic stem cells. *Biochem. Biophys. Res. Commun.* 359, 536–542. 85
- Zhang, Y., Huang, S., Dong, W., Li, L., Feng, Y., Pan, L., Han, Z., Wang, X., Ren, G., Su, D., Huang, B., Lu, J., 2008. SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. *Cancer Lett.* 67